Second Positive Phase 3 Dupixent® (dupilumab) Trial Con

Second Positive Phase 3 Dupixent® (dupilumab) Trial Confirms Significant Improvements for Patients with Prurigo Nodularis

Second Positive Phase 3 Dupixent® (dupilumab) Trial Confirms Significant Improvements for Patients with Prurigo Nodularis

streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

Japan , Paris , France General , France , Regeneron Velocimmune Technologyregeneron , Georged Yancopoulos , Naimish Patel , Regeneron Pharmaceuticals Inc , Twitter , Regeneron Genetics Center , Nasdaq , Teva Pharmaceutical Industries Ltd , Exchange Commission , Head Of Global Development , Dupilumab Development Programdupilumab , Chief Scientific Officer , Global Development , Worst Itch Numeric Rating Scale , Global Assessment , Velocimmune Technologyregeneron , Chief Scientific Officer George , Development Programdupilumab , Prescribing Informationincluding Patient , Forward Looking Statements , Digital Mediathis , Regeneron Pharmaceuticals , Product Candidates , Teva Pharmaceutical Industries ,